Lisa Patel

Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. It focuses on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom.

Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Istesso Ltd. Operates as a drug discovery and development company. The company was founded in 2017 and is headquartered in London, the United Kingdom.